Table 3.

ANA and anti-dsDNA antibodies in patients treated with anti-TNFα agents.

Author	Disease	N	Drugs	ANA		dsDNA
Baseline (%)	End (%)	Baseline (%)	End (%)
Hanauer et al. (2002) [40]	Crohn's	188	Infliximab (5mg/kg)	–	56	–	34
				385	Infliximab (10 mg/kg)	–	35	–	11
Allanore et al. (2004) [41]	RA	59	Infliximab	29	69	3	32
Ferraro-Peyret et al. (2004) [42]	RA	24	Infliximab	37.5	87.5	4.2	57
	AS	15	Infliximab	13.3	66.7	13.3	31
Caramaschi et al. (2004) [43]	RA	43	Infliximab	37	95	0	2.6
			11	Etanercept	36	55	0	0
Eriksson et al. (2005) [44]	RA	53	Infliximab	24	69	2	45
Sellam et al. (2005) [45]	SpA	33	Infliximab	4	29	0	11
Klareskog et al. (2005) [46]		RA	549	Etanercept	–	–	0.4	2–4
De Rycke et al. (2005) [47]	RA	59	Infliximab	40	85	0	40
		SpA	54	Infliximab	12	62	0	55
		20	Etanercept	15	30	0	15
Atzeni et al. (2006) [48]	RA	57	Adalimumab	7	28	0	7
Poulalhon et al. (2007) [49]	Psoriasis	28	Infliximab	12	72	0	68
Bacquet-Deschryver et al. (2008) [50]	RA	48	Infliximab	0	62.5	0	3
			30	Etanercept	0	13.3	0	0
		17	Adalimumab	0	29.4	0	0
	SpA	44	Infliximab	0	47.7	0	0
			29	Etanercept	0	14.3	0	3.4

Abbr.: RA, rheumatoid arthritis; AS, ankylosing spondylitis; SpA, spondyloarthropathy; ANA, antinuclear antibodies; dsDNA, double-stranded deoxyribonucleic acid antibodies.